In a Japanese phase III trial (NINJA) reported in the Journal of Clinical Oncology, Hamanishi et al found that nivolumab did not improve overall survival vs chemotherapy with either gemcitabine or pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer.
Study … Read more
By Hayley Virgil
Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.
The National Comprehensive Cancer Network (NCCN) has announced a significant … Read more
By Meg Tully
Rosemary Jemo volunteered for a blood test trial based on pioneering research from Johns Hopkins University because she thought it would be great if it could save lives.
The 71-year-old Pennsylvania hairdresser now believes that decision saved … Read more
A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more
By Alan P. Lyss, MD
The COVID-19 pandemic prompted changes to standard practices for cancer clinical trials, and thought leaders have recommended continuing — and improving upon — those new practices.
These recommendations, from members of the American Association for … Read more
A gene called DOT1L appears to play a role in progression and severity of ovarian cancer, and inhibitors of the DOT1L enzyme may offer a new therapeutic approach for the disease, University of Alabama at Birmingham researchers say in a … Read more
By Ariana Pelosci
Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.
The identification of social needs and accompanying solutions could result in more actionable health care disparities … Read more
DALLAS – July 30, 2021 – UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.… Read more
For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.
The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more
Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station.… Read more
A new study published online today in the Journal of the National Cancer Institute reports that one third of the most popular cancer treatment articles on social media contain misinformation. Further, the vast majority of that misinformation has the potential … Read more
The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.
The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more
By Ariana Pelosci
A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.
Although hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin appeared to be well tolerated in patients … Read more
CAMBRIDGE, England — Virtual biopsies could replace invasive tissue procedures and give more accurate results thanks to a revolutionary new method developed using computer scans. The new advanced computing technique uses routine medical scans to enable doctors to take fewer, … Read more
By Alan Mozes
Could a new one-and-done blood test designed to detect as many as 50 different types of cancer become a diagnostic game changer?
Yes, say researchers, who report the method appears accurate and reliable at identifying and locating … Read more
Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more
Dampened responses seen in those with hematological malignancies, however
by Mike Bassett
Patients with cancer who were vaccinated against COVID-19 achieved high seroconversion rates, a single-center study found.
The rate of seroconversion was especially high among patients with solid tumors … Read more
A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more
Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1… Read more
Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.… Read more
